A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2015
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Acronyms NICAP
- Sponsors Eurofarma
- 24 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 15 Aug 2013 Planned number of patients changed from 304 to 280 as reported by ClinicalTrials.gov.
- 15 Aug 2013 Planned initiation date changed from 1 Sep 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.